CTI announces last pixantrone clinical trial style for treatment of DLBCL Cell Therapeutics.

Bianco. In December 2010, CTI submitted a formal appeal to the FDA’s Office of New Medications in the FDA’s Center for Medication Evaluation and Research regarding its 2010 decision about CTI’s new medication program for pixantrone. CTI recently met with the OND to go over the appeal. The OND requested, and CTI programs to supply the FDA with, additional analyses from the PIX 301 trial. CTI expects a decision regarding its charm early in the second one fourth of 2011. Related StoriesFranziska Michor called recipient of NYSCF – Robertson Stem Cell PrizeChemotherapy-induced nausea and vomiting most common distressing symptoms in majority of cancers patientsBlood stem cell self-renewal reliant on surroundingsIn Europe, the Marketing Authorization Program for pixantrone as monotherapy for individuals with relapsed or refractory aggressive NHL is currently under review by the European Medications Agency based on the pixantrone phase III study results.User Group Meeting. October 21 and 22 in Boston The User Group Meeting will need place. Sara Gambrill is a highly respected and sought-after speaker in the pharmaceutical arena. She writes insightful feature tales about international and domestic clinical research industry trends regularly for The CenterWatch Monthly and CWWeekly. Ms. Gambrill has also written special reports about various clinical research market regions. It shall offer an excellent learning experience for every attendee. Gambrill will focus on topics including developments and data about technology adoption in the scientific research space.

Other Posts From Category "men's health":

Related Posts